DIFFERENCES IN UTILIZATION OF AUTOLOGOUS STEM CELL TRANSPLANT BY ETHNICITY

DO WE NEED TO FOCUS ON THIS AS A BARRIER TO TRANSPLANT?
PRIMARY FOCUS ON BARRIERS TO TRANSPLANT HAS BEEN ON ALLOGENEIC TRANSPLANT
Annual Number of Transplant Recipients in the US by Transplant Type

*2014 Data incomplete
Trends in Autologous Transplants by Recipient Age*

*Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma
Indications for Hematopoietic Stem Cell Transplants in the US, 2013

- **Allogeneic** (Total N=8,197)
- **Autologous** (Total N=11,258)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Allogeneic</th>
<th>Autologous</th>
</tr>
</thead>
<tbody>
<tr>
<td>Myeloma / PCD</td>
<td>6,000</td>
<td>5,000</td>
</tr>
<tr>
<td>AML</td>
<td>3,000</td>
<td>2,000</td>
</tr>
<tr>
<td>ALL</td>
<td>1,000</td>
<td>1,000</td>
</tr>
<tr>
<td>CML</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>NHL</td>
<td>3,000</td>
<td>3,000</td>
</tr>
<tr>
<td>HD</td>
<td>1,000</td>
<td>1,000</td>
</tr>
<tr>
<td>MDS/MPD</td>
<td>1,000</td>
<td>1,000</td>
</tr>
<tr>
<td>CLL</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>Aplastic Anemia</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>Other Non-Malignant Dis</td>
<td>500</td>
<td>500</td>
</tr>
<tr>
<td>Other Cancer</td>
<td>500</td>
<td>500</td>
</tr>
</tbody>
</table>
Survival after Autologous Transplants for Multiple Myeloma, 2000-2013

- 2000-2003 (n=8,432)
- 2004-2007 (n=10,760)
- 2008-2011 (n=15,617)
- 2012-2013 (n=9,706)

By Year of Transplant
<table>
<thead>
<tr>
<th>Disease</th>
<th>ODDS RATIO</th>
<th>P VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Diseases</td>
<td>1.4</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Autologous Transplants</td>
<td>1.24</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>NHL</td>
<td>2.03</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>MM</td>
<td>1.72</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

Joshua et al: Access to Hematopoietic Stem Cell Transplantation Effect of Race and Gender Cancer 2010
Race And Outcomes Of Autologous Hematopoietic Cell Transplantation For Multiple Myeloma


Biology of Blood and Marrow Transplantation
Volume 16, Issue 3, Pages 395-402 (March 2010)
DOI: 10.1016/j.bbmt.2009.11.007
FIGURE 1.

White (N = 1,850)

African-American (N = 296)

CI of NRM: White 8%, African-American 9%, P-value 0.52
FIGURE 2.

Cumulative Incidence, %

White (N = 1,850)

African-American (N = 296)

CT of Relapse
White 72%
African-American 72%
P-value 0.97
Figure 3.
FIGURE 4.

![Graph showing adjusted probability for African-American and White patients over five years.](image-url)

- **African-American (N = 303)**
- **White (N = 1,892)**

**CI of OS @5 years**
- White: 47%
- African-American: 52%
- P-value: 0.19
Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma

Luciano J. Costa, Jia-Xing Huang, Parameswaran N. Hari

Biology of Blood and Marrow Transplantation
Volume 21, Issue 4, Pages 701-706 (April 2015)
DOI: 10.1016/j.bbmt.2014.12.024
FIGURE 1.
- Data does not capture all transplant activity
- Data does not capture reasons for apparent differences in activity
Subcommittee of this group to consider developing consensus guidelines to study and try to understand if this is a problem

Work with other interest groups CIBMTR/ASBMT/ASH